DAFS Utils Anonymizer
Remove DICOM header information at click of a button
Software · On PremiseCompany source
Company profile
About Voronoi Health Analytics
Voronoi Health Analytics is a medical imaging AI company specializing in automated segmentation and quantitative analysis of CT, PET/CT, and MRI scans. Founded on over a decade of body composition research, the company has developed the Data Analysis Facilitation Suite (DAFS), an FDA 510(k) cleared Class II medical device that transforms medical images into actionable clinical data. The platform automates whole-body anatomical digitization, including body composition analysis, organ and tumor volumetry, cardiac CT coronary artery analysis, PET/CT metabolic activity quantification, and whole-body MRI analysis. DAFS serves multiple healthcare sectors including oncology, cardiology, nutrition sciences, geriatrics, and pharmaceutical research. The company offers several product variants: DAFS for comprehensive whole-body analysis on PC or server, DAFS Express for rapid single-slice body composition analysis, DAFS Node as a bi-directional DICOM gateway for PACS integration, and DAFS Anonymizer for data privacy. Beyond software licensing, Voronoi provides full-service project reading services, handling data preprocessing, accurate measurement extraction, custom report generation, and statistical analysis. The company's technology is backed by extensive peer-reviewed publications and has been validated across numerous clinical studies. Voronoi Health Analytics serves researchers, radiologists, data scientists, and clinicians seeking to convert complex imaging data into precise, quantitative biomarkers that support diagnostic accuracy, clinical workflows, and research outcomes.
Company description Voronoi Health Analytics official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Voronoi Health Analytics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Body composition disorders
- Cancer (NSCLC, colorectal liver metastases, pancreatic, hepatic, gastric, esophageal)
- Cardiovascular disease
- COPD
- Metabolic disease
- Sarcopenia and frailty
- Tumor volumetry and staging
Who it serves
- Academic researchers
- Cardiologists
- Clinical researchers
- Data scientists
- Health systems
- Oncologists
- Pharmaceutical companies
- Radiologists
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: PACS systems via DICOM SCU/SCP protocol.
Geographic context
MarketsGlobal research institutions · North America
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance (K253944) for DAFS-CT as Class II Software Medical Device, enabling clinical deployment (announced 2024-2026 timeframe based on website update)
Partnerships
Recorded partners
- National Cancer Institute (NCI) - presented at webinar series
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Data Analysis Facilitation Suite (DAFS)
Automated total body CT, PET/CT, and MR quantification and visualization
Software · On PremiseCompany source
Data Analysis Facilitation Suite Express (DAFS Express)
Lightweight and rapid single slice body composition analysis for CT and MR
Software · On PremiseCompany source
Data Analysis Facilitation Suite Node (DAFS Node)
Bi-Directional DICOM gateway (SCU/SCP) for seamless AI analysis in the PACS ecosystem
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Prediction of Whole-Body Tissue Composition from Regional Sub-Body CT Scans.Journal of imaging informatics in medicine · Jul 21, 2026
Automated three-dimensional body composition analysis identifies visceral adipose tissue radiodensity as a predictor of mortality and recurrence in colorectal cancer.Clinical nutrition (Edinburgh, Scotland) · Aug 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Data Analysis Facilitation Suite (DAFS)K253944 · 510k · Mar 16, 2026
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Automated whole-body anatomical digitization
CT, PET/CT, and MRI quantification and visualization
Body composition analysis
Skeletal muscle volume, adipose tissue, organ volumes, radiodensity measurements
Tumor and lesion volumetry
Total metabolic tumor volume, PSMA PET-derived volumes, change over time tracking
Risk stratification improvement
Colorectal liver metastases patients through volumetric body composition analysis
Prognostic value
Skeletal muscle gauge as survival predictor in early-stage NSCLC
Body Composition Research - Mushfiqus Salehin et al.
Validation of automated computed tomography segmentation software to assess body composition among cancer patients
Validated automated CT segmentation for body composition analysis in cancer patient population
Cancer Research Study - Arsalan Khan et al.
Postoperative sarcopenia assessment and association with recurrence in resected early-stage non-small cell lung cancer patients
Successfully analyzed 233 patients, identifying that skeletal muscle volume loss >1% was associated with worse disease-free survival (hazard ratio 2.93, 95% CI 1.42 to 6.04, p = 0.004)
Colorectal Liver Metastases Study - Qiang Wang et al.
Improved risk stratification in patients with colorectal liver metastases by incorporating volumetric body composition analysis
Enhanced risk stratification through volumetric body composition analysis
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Voronoi Health Analytics
Recent articles published on Voronoi Health Analytics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.